Results 161 to 170 of about 173,582 (279)

Providing holistic care for patients with metabolic dysfunction‐associated steatotic liver disease/metabolic dysfunction‐associated steatohepatitis: Key aspects of clinical assessment and how to develop individualised care plans for surveillance and interventions

Diabetes, Obesity and Metabolism, EarlyView.
Abstract Metabolic dysfunction‐associated steatotic liver disease (MASLD), characterised by hepatic steatosis and metabolic dysfunction (i.e., obesity, type 2 diabetes, dyslipidaemia, and hypertension), is affecting over 30% of the adult population worldwide.
Lanlan Chen, Paul Horn, Frank Tacke
wiley   +1 more source

Development and validation of a high-confidence diagnostic model integrating ctDNA methylation and serum biomarkers for early-stage hepatocellular carcinoma detection. [PDF]

Mol Biomed
Wu H, Wang M, Wan Z, Yao L, Zhou S, Wang H, Lv G, Wang N, Wang F, Xu J, Xu X, Li C, Diao Y, Pawlik TM, Liu R, Shen F, Yang T.   +16 more
europepmc   +1 more source

Winter‐active spiders (Clubiona) have a hyperactive antifreeze protein with a unique beta‐solenoid fold

The FEBS Journal, EarlyView.
Antifreeze proteins from winter‐active spiders were purified using their affinity for ice. After LC–MSMS characterization, corresponding transcripts were identified. The antifreeze protein folds as a β‐solenoid with a large flat ice‐binding site on one surface and can bind to ice crystals and prevent their growth at −4 °C.
Laurie A. Graham, Stano Pekár, Ina M. Hainer, Peter L. Davies   +3 more
wiley   +1 more source

Discovering naturally occurring antifreeze peptides from microbiome by integrating protein language models and molecular dynamics simulation. [PDF]

J Mater Chem B
Imam IA, Morey T, Jiang Y, Wang D, Xu D, Shao Q.   +5 more
europepmc   +1 more source

Impact of Early‐Line Systemic Therapies on Liver Function in Hepatocellular Carcinoma: Longitudinal Change of ALBI Score and Ammonia Level With and Without Anti‐VEGF Agents

Hepatology Research, EarlyView.
ABSTRACT Background and Aim Anti–vascular endothelial growth factor (VEGF) agents are widely used for hepatocellular carcinoma (HCC); inhibition of VEGF‐mediated liver regeneration may compromise hepatic reserve. We investigated the impact of anti‐VEGF therapy on liver function and risk factors for deterioration of albumin–bilirubin (ALBI) score during
Naoshi Nishida, Kazuomi Ueshima, Tomoko Aoki, Takuya Matsubara, Naoya Omaru, Natsuki Okai, Masahiro Morita, Hirokazu Chishina, Masahiro Takita, Satoru Hagiwara, Yasunori Minami, Masatoshi Kudo   +11 more
wiley   +1 more source

Performance Assessment of μTASWako i50, a New Microfluidic Immunoassay System for Hepatocellular Carcinoma Biomarkers AFP, AFP-L3%, and PIVKA-II. [PDF]

Cureus
Yoshikawa T, Ohtsubo T, Yamaguchi I, Nishihara H, Mori Y, Yamada H, Toyoda H, Kawabata T, Matsuda S.   +8 more
europepmc   +1 more source

Efficacy and Safety of Second‐Line Lenvatinib After First‐Line Durvalumab Plus Tremelimumab in Unresectable Hepatocellular Carcinoma

Hepatology Research, EarlyView.
ABSTRACT Background There is a paucity of data regarding the efficacy and safety of lenvatinib as a second‐line treatment following first‐line combination immunotherapy with durvalumab and tremelimumab (Dur + Tre). Methods This retrospective multicenter study included 14 patients with unresectable hepatocellular carcinoma who received lenvatinib after ...
Ryoichi Miura, Tomokazu Kawaoka, Saki Sueda, Aiko Tanaka, Kou Hashimoto, Tomoaki Emori, Yasutoshi Fujii, Hatsue Fujino, Atsushi Ono, Eisuke Murakami, Daiki Miki, Shinsuke Uchikawa, Nami Mori, Keiji Tsuji, Yosuke Suehiro, Keiichi Masaki, Michihiro Nonaka, Kenji Yamaoka, Yoshio Katamura, C. Nelson Hayes, Masataka Tsuge, Shiro Oka   +21 more
wiley   +1 more source

AFP confers the resistance of lenvatinib in hepatocellular carcinoma by activating PI3K/AKT/LDHA signaling axis. [PDF]

Discov Oncol
Xing W, Wang F, Feng S, Li X, Zhou Y, Wu H, Lin B, Dong X, Li M, Zhu M.   +9 more
europepmc   +1 more source

Borderline Resectable Classification Identifies Candidates for Conversion Therapy in Unresectable Hepatocellular Carcinoma Treated With Atezolizumab and Bevacizumab

Hepatology Research, EarlyView.
ABSTRACT Background Conversion therapy, which seeks to achieve curative treatment following systemic therapy, is increasingly acknowledged in the management of unresectable hepatocellular carcinoma (HCC). However, validated criteria for predicting eligibility for conversion remain unclear. We investigated the utility of the recently proposed borderline
Yasuto Takeuchi, Masahiko Sue, Nozomi Miyake, Takuya Adachi, Hideki Onishi, Miwa Kawanaka, Akinobu Takaki, Kazuhiro Nouso, Kazuya Kariyama, Shinichiro Nakamura, Emi Tanaka, Toshifumi Tada, Tetsuya Yasunaka, Kenji Kuwaki, Junichi Toshimori, Shota Iwado, Akio Moriya, Hiroaki Hagihara, Hiroyuki Takabatake, Masahiro Sakata, Motoyuki Otsuka   +20 more
wiley   +1 more source

Conversion Surgery for Alpha-Fetoprotein-Producing Esophagogastric Junction Cancer with Multiple Liver Metastases and Portal Vein Tumor Thrombus after Nivolumab Combination Chemotherapy: A Case Report and Literature Review. [PDF]

Surg Case Rep
Akai M, Takagi S, Toji T, Mitani Y, Shimabara M, Nobunaga Y, Matsumura T, Inoue M.   +7 more
europepmc   +1 more source